Sputnik V Archives

A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits

One of this and one of that might be a good strategy to coronavirus vaccination. SOPA Images/LightRocket via Getty Images Maureen Ferran, Rochester Institute of Technology While it’s now pretty easy to get a COVID-19 shot in most places in the U.S., the vaccine rollout in other parts of the world has been slow or inconsistent due to shortages, uneven …

Russian COVID vaccine: why more and more countries are turning to Sputnik V

Sarah Schiffling, Liverpool John Moores University and Liz Breen, University of Bradford When the Russian president, Vladimir Putin, announced on August 11 2020 that the country’s health regulator had become the first in the world to approve a COVID-19 vaccine for widespread use, the news was greeted with scepticism. No trials had been completed on the vaccine’s safety and efficacy. …

Vaccine diplomacy: how some countries are using COVID to enhance their soft power

Michael Jennings, SOAS, University of London The COVID-19 pandemic has given rise to various new, repurposed or newly popular terms. The newest entry to the pandemic lexicon might be “vaccine diplomacy”, with some countries using their jabs to strengthen regional ties and enhance their own power and global status. In early February, half a million doses of the Chinese Sinopharm …

Por qué nos ha sorprendido la vacuna rusa Sputnik V

sputnikvaccine.com Matilde Cañelles López and María Mercedes Jiménez Sarmiento, Centro de Investigaciones Biológicas Margarita Salas (CIB – CSIC) Estos días hemos asistido a la publicación en la prestigiosa revista The Lancet de los resultados del ensayo clínico de la vacuna rusa Sputnik V. Estos han causado gran revuelo, ya que posicionan a esta vacuna como una de las más prometedoras …

COVID-19 vaccines: how and when will lower-income countries get access?

Rory Horner, University of Manchester COVID-19 vaccination programmes are gathering pace in high-income countries, but for much of the world, the future looks bleaker. Although a number of middle-income countries have started rolling out vaccines, widespread vaccination could still be years away. The first two COVID-19 vaccines authorised in Europe and the United States – made by Pfizer/BioNTech and Moderna …

Coronavirus: why combining the Oxford vaccine with Russia’s Sputnik V vaccine could make it more effective

Jim Barber/Shutterstock Jameel Inal, University of Hertfordshire When the efficacy of the Oxford/AstraZeneca vaccine was announced in late 2020, there was some confusion. The overall efficacy of the vaccine at stopping people developing symptomatic COVID-19, two weeks after the second dose, was 70%. But this wasn’t the whole picture. This figure was based on averaging the results from two groups. …